ValiRx plc is listed on AIM of the London Stock Exchange under the ticker code VAL.
There are no restrictions on the transfer of ValiRx’s shares and these are not listed on any other exchange.
Valirx aims to deliver high returns by applying its scientific, management and entrepreneurial expertise to projects in which it has equity and rights. These projects have intelligent acquisition and manageable development costs, but have the potential to significantly increase in value prior to their crystalisation.
We are building a portfolio of innovative products through strategic investment into areas relating to the treatment and diagnosis of cancer. We work regularity with companies offering technologies complementary to our own.
The diversity and number of projects we undertake ensures we spread our investment risk, whilst our business model seeks to minimise the level of financial exposure associated with research and development.